Quotes 5-day view Delayed Nasdaq
1 198 014
1 716 752
Estimated financial data (e) (USD)
1 089 M
Net income 2022
Net cash position 2022
1 216 M
P/E ratio 2022
1 608 M
Net income 2023
Net cash position 2023
1 283 M
P/E ratio 2023
17 911 M
17 911 M
EV / Sales 2022
EV / Sales 2023
Nbr of Employees
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based...
Ratings of Alnylam Pharmaceuticals, Inc.
All news about ALNYLAM PHARMACEUTICALS, INC.
06/27 EUCOPE Member Spotlight, Q&A with Alnylam
06/27 Guggenheim Downgrades Alnylam Pharmaceuticals to Neutral From Buy
06/15 SVB Securities Adjusts Price Target on Alnylam Pharmaceuticals to $98 From $96, Maintai..
06/14 SECTOR UPDATE : Health Care Stocks Finish Above Tuesday's Worst Levels
06/14 SECTOR UPDATE : Health Care Stocks Declining in Tuesday Trading
06/14 SECTOR UPDATE : Health Care Stocks Climb Pre-Bell Tuesday
06/14 TRANSCRIPT : Alnylam Pharmaceuticals, Inc. - Special Call
06/14 ALNYLAM PHARMACEUTICALS : Announces FDA Approval of AMVUTTRA (vutrisiran), an RNAi T..
06/14 ALNYLAM PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
06/14 Alnylam Pharmaceuticals Says FDA Approves Amvuttra to Treat Polyneuropathy Caused by Ra..
06/13 Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for..
06/13 Alnylam Announces FDA Approval of AMVUTTRA, an RNAi Therapeutic for the Treatment of th..
06/13 TRANSCRIPT : Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 43rd Annual Global He..
06/09 TRANSCRIPT : Alnylam Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Co..
06/09 Alnylam Pharmaceuticals Says Cemdisiran Product Meets Primary Endpoint of Immunoglobuli..
News in other languages on ALNYLAM PHARMACEUTICALS, INC.
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
Pfizer's $11.6 billion Biohaven buy could spark more biotech deals
Chart ALNYLAM PHARMACEUTICALS, INC.
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short Term Mid-Term Long Term Trends Bullish Neutral Bearish
Number of Analysts
Last Close Price
Average target price
Spread / Average Target